01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Inflammatory breast cancer is defined by its rapid clinical pattern rather than by a unique microscopic cell type. Tumour emboli obstruct dermal lymphatic channels, producing skin oedema, erythema and enlarged follicular openings that create peau d’orange. The primary invasive carcinoma may be difficult to feel because disease permeates tissue diffusely. Infection can coexist, but absence of a drainable collection and failure of appropriate antibiotics should accelerate, not postpone, biopsy.
The diagnostic objective is to prove invasive carcinoma, document receptor biology, assess axillary nodes and establish whether distant metastases are present. Skin punch biopsy may show dermal lymphatic tumour emboli, yet a negative punch does not exclude the clinical diagnosis because involvement is patchy. In non-metastatic disease, systemic therapy comes before local surgery to treat occult systemic risk and assess response. The pretreatment extent remains relevant even when the breast improves dramatically.
Key points
- Inflammatory breast cancer is an aggressive clinical presentation of invasive carcinoma causing rapid diffuse breast erythema, oedema and enlargement through dermal lymphatic obstruction.
- A discrete mass may be absent. Peau d’orange, warmth, heaviness, tenderness, nipple flattening and regional nodes can resemble mastitis, cellulitis or an abscess.
- Ask about lactation, fever, systemic toxicity, symptom speed and antibiotic response, but do not require infection to be excluded for weeks before arranging cancer assessment.
- Diagnostic work-up uses breast and axillary imaging plus core biopsy of a representative breast target; add skin punch biopsy when dermal lymphatic involvement needs evaluation, recognising patchy sampling.
- Stage the patient before curative treatment because the clinical phenotype is locally advanced and has a substantial risk of nodal or distant disease.
- For non-metastatic inflammatory cancer treated with neoadjuvant chemotherapy, NICE recommends mastectomy, or breast conservation only exceptionally, followed by radiotherapy.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Aggressive invasive carcinoma
Multiple invasive breast cancer subtypes can produce the inflammatory phenotype; it is not a separate benign inflammatory disorder.
Molecular tumour drivers
HER2-positive, hormone-receptor-positive and triple-negative biology can each occur, so receptor testing is necessary rather than assumed from appearance.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Dermal lymphatic obstruction
Tumour emboli enter and block superficial lymphatic channels, preventing normal drainage and producing oedematous thickened skin.
- 2Diffuse stromal infiltration
Cancer permeates a broad breast volume rather than forming only one circumscribed mass, causing rapid firmness and enlargement.
- 3Peau d’orange formation
Fluid accumulates around fixed hair follicles and suspensory attachments, leaving pits between swollen areas and an orange-peel contour.
- 4Early dissemination risk
Extensive lymphovascular access contributes to frequent regional nodal involvement and a meaningful probability of distant metastasis at diagnosis.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Symptoms evolve over days to weeks with substantial erythema, swelling, warmth or heaviness involving a broad area rather than one small inflamed focus.
Oedema tethers skin around follicles, creating an orange-peel surface that reflects impaired dermal lymphatic drainage.
Diffuse infiltrative growth can produce firmness and enlargement without a single palpable lesion, so a mass is not required for suspicion.
Enlarged or morphologically abnormal axillary, internal mammary or supraclavicular nodes often accompany the presentation and influence stage and radiotherapy planning.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Diagnostic mammography and breast ultrasoundFirst step - Why
- Find a representative breast target, assess diffuse structural change and guide core biopsy.
- Interpretation and limitations
- Skin thickening and diffuse density may be visible without a single mass. Non-diagnostic imaging does not exclude disease when the clinical phenotype remains compelling.
- 02
Breast core biopsy - Why
- Confirm invasive carcinoma and provide tissue for grade, ER, PR and HER2 assessment.
- Interpretation and limitations
- Representative invasive tumour is essential before systemic treatment. A benign result that does not explain diffuse progressive change requires repeat targeted sampling.
- 03
Axillary ultrasound and node sampling - Why
- Establish regional nodal involvement and obtain tissue if the breast target is difficult or additional confirmation is needed.
- Interpretation and limitations
- A positive node confirms regional spread but pathology must establish breast origin. A normal scan cannot erase clinically suspicious supraclavicular or diffuse breast findings.
- 04
Staging and skin biopsy - Why
- Assess distant disease and document dermal lymphatic involvement where useful for diagnostic concordance.
- Interpretation and limitations
- CT-based staging follows specialist protocol. A positive skin punch supports the phenotype; a negative punch has limited exclusion value because emboli are unevenly distributed.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Bacterial mastitis
Focal erythema, fever and breast pain may improve with effective antibiotics and physiological milk drainage; persistent diffuse change requires reassessment.
Breast abscess
Ultrasound demonstrates a drainable fluid cavity, although infection and cancer can coexist and residual solid tissue still needs explanation.
Granulomatous mastitis
Sterile or Corynebacterium-associated lobulocentric inflammation can cause masses, sinuses and peau d’orange and requires core-based exclusion of malignancy.
Severe lymphatic oedema
Cardiac failure or prior lymphatic treatment can swell breast skin, but tempo, laterality, systemic context and tissue assessment distinguish causes.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Non-resolving inflammation pathwayMove from infection treatment to tissue diagnosisFirst stepA non-lactating 49-year-old has three weeks of diffuse erythema and peau d’orange, no drainable collection and no improvement after appropriate antibiotics.+
- 1Assess observations and sepsis immediately, record the area and tempo of skin change, examine both breasts and all regional nodal basins.
- 2Arrange urgent diagnostic mammography, breast and axillary ultrasound, targeting any mass, distortion or abnormal node for tissue.
- 3Obtain core biopsy of representative breast abnormality and add nipple or skin punch tissue when clinically indicated; request ER, PR and HER2 with invasive histology.
- 4Complete specialist staging promptly and discuss the case at the breast multidisciplinary meeting without cycling through further empirical antibiotics.
- 5If non-metastatic inflammatory carcinoma is confirmed, begin agreed neoadjuvant systemic therapy, document clinical and imaging baseline, then verify response before local treatment.
02Curative-intent sequenceSystemic treatment before local controlCore confirms non-metastatic HER2-positive inflammatory breast carcinoma with regional nodal involvement.+
- 1Agree biology-directed neoadjuvant chemotherapy and HER2-targeted treatment through oncology, with baseline cardiac assessment for the selected regimen.
- 2Monitor skin extent, breast volume, nodes and treatment toxicity while completing planned systemic therapy; investigate progression rather than waiting for the final cycle.
- 3After response assessment, offer mastectomy, or breast-conserving surgery only in exceptional circumstances selected by the multidisciplinary team.
- 4Follow surgery with radiotherapy planned from pretreatment stage and pathological response, then complete indicated systemic and surveillance care.
03Metastatic presentation pathwayPrioritise biopsy, biology and symptomsStaging demonstrates liver metastases at the time inflammatory breast cancer is diagnosed.+
- 1AlternativeConfirm metastatic disease radiologically and obtain representative pathology if receptor discordance or an alternative diagnosis would change treatment.
- 2Discuss prognosis and goals sensitively, assess pain, skin breakdown, infection, breathlessness, nutrition and psychosocial needs.
- 3Select systemic therapy from receptor status, disease tempo, organ function and patient preference; use local radiotherapy or surgery only for defined symptom-control goals.
- 4Reassess early for response and toxicity and involve specialist palliative care alongside active oncology when symptom burden is substantial.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Distant metastasis
Early haematogenous and lymphatic dissemination may involve bone, liver, lung or brain and changes the goal of treatment.
Chest-wall recurrence
Diffuse residual microscopic disease can recur across the chest wall or regional lymphatics despite an initial visible response.
Skin breakdown and infection
Progressive tumour can ulcerate, ooze, bleed and become secondarily infected, causing pain, odour and major psychosocial distress.
Lymphoedema
Heavy nodal disease, axillary treatment and regional radiotherapy all increase later arm and chest-wall lymphatic morbidity.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Photograph or map pretreatment skin extent with consent, document breast and nodal findings, and preserve baseline imaging for later response comparison.
- During neoadjuvant therapy, monitor regimen-specific blood counts, organ function, infection risk and cardiac function where HER2-directed treatment requires it.
- At response review, compare the complete clinical and imaging pattern with baseline; disappearance of redness does not downstage the original inflammatory presentation automatically.
- After local treatment, monitor chest-wall and regional recurrence, lymphoedema, shoulder function, radiotherapy toxicity and distant symptoms through the agreed specialist pathway.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Clinical phenotype leads
Dermal lymphatic emboli support the diagnosis but can be missed in a punch; rapid diffuse change plus proven invasive carcinoma remains clinically decisive.
No lump is required
Inflammatory cancer permeates tissue and lymphatics, so insisting on a discrete mass delays diagnosis in the very presentation that is characteristically diffuse.
Response does not erase baseline
Neoadjuvant therapy can normalise skin appearance, but radiotherapy and surgical planning retain the original locally advanced distribution and nodal burden.
Infection and cancer can coexist
Fever or partial antibiotic improvement does not permanently close the cancer pathway when persistent peau d’orange, mass or nodes remain unexplained.
11Common pitfallsFrequent interpretation and management errors.
- 01
Requiring several failed antibiotic courses before referral loses critical time when early imaging shows no collection and the breast remains diffusely abnormal.
- 02
Using a negative skin punch to rule out inflammatory cancer overestimates a test vulnerable to patchy dermal lymphatic involvement.
- 03
Operating first on confirmed non-metastatic inflammatory cancer bypasses neoadjuvant systemic treatment and the NICE local-treatment sequence.
- 04
Treating visible skin response as proof that all pretreatment disease has vanished can lead to inadequate surgery or radiotherapy coverage.